Selective glucocorticoid receptor modulation maintains bone mineral density in mice

Journal of Bone and Mineral Research

Volumn 27, Issue 11, 2012, Pages 2242-2250

  Thiele, Sylvia ^a   Ziegler, Nicole ^a   Tsourdi, Elena ^a   De Bosscher, Karolien ^b,c   Tuckermann, Jan P ^d   Hofbauer, Lorenz C ^a   Rauner, Martina ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

BONE REMODELING; COMPOUND A; DKK 1; GLUCOCORTICOID INDUCED OSTEOPOROSIS; RANKL

Indexed keywords

ALKALINE PHOSPHATASE; COMPOUND A; DICKKOPF 1 PROTEIN; GLUCOCORTICOID RECEPTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; PROCOLLAGEN C PROTEINASE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TISSUE; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FEMUR; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; SKELETON; SPINE; SPLEEN; STROMA CELL; TRABECULAR BONE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; CELL DIFFERENTIATION; GLUCOCORTICOIDS; HUMANS; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; RECEPTORS, GLUCOCORTICOID;

EID: 84867559755     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1688     Document Type: Article

References (28)

1. Rachner TD, Khosla S, Hofbauer LC., Osteoporosis: now and the future. Lancet. 2011; 377: 1276-87.
2. Hofbauer LC, Rauner M., Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009; 23: 1525-31.
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP., Glucocorticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18: 1319-28. (Pubitemid 47389469)
4. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S., Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140: 4382-9. (Pubitemid 30666099)
5. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S., Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem. 2008; 103: 335-45.
6. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG., Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009; 60: 1427-37.
7. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC., Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102: 274-82. (Pubitemid 28335186)
8. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David JP, Reichardt HM, Amling M, Schütz G, Tuckermann JP., Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010; 11: 517-31.
9. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R., Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004; 318: 259-64. (Pubitemid 38526274)
10. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL., Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 2008; 149: 1793-801.
11. Krishnan V, Bryant HU, Macdougald OA., Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116: 1202-9.
12. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H., Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 2009; 85: 538-45.
13. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G., A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A. 2005; 102: 15827-32. (Pubitemid 41552827)
14. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Müller-Ladner U, Vander Cruyssen B, Verbruggen G, Haegeman G, Elewaut D., A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol. 2008; 180: 2608-15.
15. van Loo G, Sze M, Bougarne N, Praet J, Mc Guire C, Ullrich A, Haegeman G, Prinz M, Beyaert R, De Bosscher K., Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol. 2010; 24: 310-22.
16. Rauner M, Goettsch C, Stein N, Thiele S, Bornhaeuser M, De Bosscher K, Haegeman G, Tuckermann J, Hofbauer LC., Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology. 2011; 152: 103-12.
17. Rauch A, Gossye V, Bracke D, Gevaert E, Jacques P, Van Beneden K, Vandooren B, Rauner M, Hofbauer LC, Haegeman G, Elewaut D, Tuckermann JP, De Bosscher K., An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 2011; 25: 1323-32.
18. Louw A, Swart P, de Kock SS, van der Merwe KJ., Mechanism for the stabilization in vivo of the aziridine precursor - (4-acetoxyphenyl)-2-chloro-N- methyl-ethylammonium chloride by serum proteins. Biochem Pharmacol. 1997; 53: 189-97. (Pubitemid 27013474)
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
20. Compston J., Glucocorticoid-induced osteoporosis. Horm Res. 2003; 60 (Suppl 3): 77-9. (Pubitemid 37548209)
21. Zhang Z, Zhang ZY, Schluesener HJ., Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol. 2009; 183: 3081-91.
22. Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, van den Brandt J, Lühder F, Reichardt HM., Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One. 2009; 4: e8202.
23. Owen HC, Miner JN, Ahmed SF, Farquharson C., The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007; 264: 164-70. (Pubitemid 46097311)
24. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS., Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006; 147: 5592-9. (Pubitemid 44833476)
25. Humphrey EL, Williams JH, Davie MW, Marshall MJ., Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone. 2006; 38: 652-61.
26. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H., Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231-4.
27. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA., Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17: 1235-41.
28. Bonewald LF., The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.